Skip to main content

Engineering of Mycoplasma pneumoniae as a broad-spectrum animal vaccine

Obiettivo

Mycoplasmas are the smallest cell wall less, free-living microorganisms. The lack of a cell wall makes them resistant to many of the common antibiotics. Every year, infections caused by Mycoplasmas in poultry, cows, and pigs, result in multimillion euros losses in USA and Europe. Currently, there are vaccines against M hyopneumoniae in pigs and M gallisepticum and M synoviae in poultry. However, there is no vaccination against many Mycoplasma species infecting pets, humans and farm animals (ie M bovis cow infection). Mycoplasma species in many cases are difficult to grown in axenic culture and those that grow need a complex media with animal serum. In large scale production of Mycoplasma species for vaccination aside from the high cost of animal serum, more important is the high irreproducibility in the production process and the possible contamination with animal viruses. All this together highlights what European industry needs:i) a defined cheap reproducible medium that is animal serum free and ii) an universal Mycoplasma chassis that could be used in a pipeline to vaccinate against Mycoplasma species, as well as any pathogen. M pneumoniae is an ideal starting point for designing such a vaccine chassis. It has a small genome (860 kb) and it is probably the organism with the most comprehensive systems biology data acquired so far. By genome comparison, metabolic modeling and rationally engineering its genome, we will create a vaccine chassis that will be introduced into an industrial pipeline. The process will be guided by the second world largest industry on animal vaccination (MSD), as well as a SME specialized on peptide display and screening. This will ensure the exploitation and commercialization of our work contributing to maintain Europe privileged position in this field. Our ultimate goal is to meet the needs of the livestock industry,taking care of ethical issues, foreseeable risks, and prepare effective dissemination and training material for the public.

Invito a presentare proposte

H2020-LEIT-BIO-2014-1
Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

FUNDACIO CENTRE DE REGULACIO GENOMICA
Indirizzo
Carrer Doctor Aiguader 88
08003 Barcelona
Spagna
Tipo di attività
Research Organisations
Contributo UE
€ 2 128 507

Partecipanti (7)

INTERVET INTERNATIONAL BV
Paesi Bassi
Contributo UE
€ 1 476 250
Indirizzo
Wim De Korverstraat 35
5831 AN Boxmeer
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
Francia
Contributo UE
€ 850 300
Indirizzo
147 Rue De L'universite
75007 Paris Cedex 07
Tipo di attività
Research Organisations
WAGENINGEN UNIVERSITY
Paesi Bassi
Contributo UE
€ 860 008
Indirizzo
Droevendaalsesteeg 4
6708 PB Wageningen
Tipo di attività
Higher or Secondary Education Establishments
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
Contributo UE
€ 699 977
Indirizzo
South Kensington Campus Exhibition Road
SW7 2AZ London
Tipo di attività
Higher or Secondary Education Establishments
ATG:BIOSYNTHETICS GMBH
Germania
Contributo UE
€ 897 493
Indirizzo
Weberstrasse 40
79249 Merzhausen
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
KOBENHAVNS UNIVERSITET
Danimarca
Contributo UE
€ 591 750
Indirizzo
Norregade 10
1165 Kobenhavn
Tipo di attività
Higher or Secondary Education Establishments
BIOFACTION KG
Austria
Contributo UE
€ 552 392
Indirizzo
Kundmanngasse 39/12
1030 Wien
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)